Neurodegenerative Disorders: Causes, Symptoms, and Types

Overview

Neurodegenerative disorders change how a person thinks, moves, communicates, and experiences the world around them. They often develop gradually. This makes early signs difficult to recognise and intervention more challenging once the condition progresses. Their impact extends beyond the individual, affecting families, caregivers, and the wider support system.¹

Today, we explore neurodegenerative disorders, what causes them, how they present, and what managing them looks like. This information matters not just to patients but also to families, caregivers, and anyone who wants to make informed decisions about their own health.

Neurodegenerative Disorders: Definition and Overview

The brain depends on billions of nerve cells constantly working together. Neurodegenerative disorders are conditions where those cells gradually break down and stop functioning.¹

What makes this particularly difficult is that neurons cannot replace themselves the way other cells can. Every cell that dies takes something with it, whether that is a memory, a movement, or a piece of personality. These conditions do not follow one single path, but they all move in the same direction, and that progression is what makes understanding them so important.¹

What Causes Neurodegenerative Disorders?

Neurodegenerative disorders do not have a single cause. They arise from multiple intersecting pathways.²

Each pathway can trigger neuronal damage independently, but more often acts together to accelerate progression. In most cases, several of these mechanisms are active simultaneously long before symptoms appear.²

1. Genetic Mutations

Causative genetic factors operate along two distinct lines. In monogenic forms, a single high-penetrance variant is sufficient to cause disease. In Huntington’s disease, a CAG repeat expansion in the HTT gene confers a 50% inheritance risk with each generation, and the outcome is determined by genotype alone.³

Rare autosomal dominant mutations in APP, PSEN1, and PSEN2 cause familial early-onset Alzheimer’s disease in the same way.4

In polygenic forms, no single variant decides the outcome. Instead, hundreds of common low-effect variants act cumulatively. In Parkinson’s disease, over 90 independent risk signals across 78 loci collectively shape susceptibility. This elevates risk without guaranteeing disease.⁵

2. Protein Misfolding and Aggregation

When specific proteins misfold, they form toxic oligomers and insoluble aggregates that disrupt cellular function, impair synaptic transmission, and ultimately trigger neuronal death. Amyloid-beta and hyperphosphorylated tau accumulate in Alzheimer’s disease, alpha-synuclein forms Lewy bodies in Parkinson’s disease, and TDP-43 inclusions characterise ALS.⁶

These aggregates can propagate from cell to cell in a prion-like manner, spreading pathology through interconnected brain regions. The process begins silently, often a decade or more before clinical symptoms appear.⁶

3. Neuroinflammation and Immune Attack

Chronic activation of microglia and astrocytes, the brain’s resident immune cells, is a consistent feature across all major neurodegenerative disorders. In response to misfolded proteins and cellular damage, microglia shift to a pro-inflammatory state. This releases cytokines and reactive oxygen species that damage surrounding neurons.¹, ²

In multiple sclerosis, this immune attack is the primary driver of disease. In Alzheimer’s and Parkinson’s disease, neuroinflammation amplifies the underlying pathology. This creates a self-sustaining cycle of neuronal injury and further immune activation.¹,²

4. Mitochondrial Dysfunction and Oxidative Stress

Neurons are among the most energy-dependent cells in the body, making them acutely sensitive to mitochondrial failure. Defects in the electron transport chain reduce ATP production, impair calcium homeostasis, and generate excessive reactive oxygen species. This oxidative stress damages proteins, lipids, and DNA, accelerating the misfolding of disease-relevant proteins.²

Impaired mitophagy, the process by which damaged mitochondria are cleared, allows dysfunctional organelles to accumulate and amplify cellular stress. Mitochondrial dysfunction is documented in Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and ALS.²

5. Environmental and Other Factors

External exposures interact with genetic vulnerability to determine who develops disease and when. Long-term contact with certain pesticides and solvents is consistently associated with elevated Parkinson’s disease risk.⁷

Repeated head trauma is causally linked to chronic traumatic encephalopathy, a progressive tauopathy that can surface years after the original injuries occurred.⁸ Ageing itself is the single largest risk modifier. The accumulation of cellular damage, declining proteostasis, and reduced mitochondrial efficiency together lower the threshold for neurodegeneration.

List of Neurodegenerative Disorders

Neurodegenerative disorders cover a wider range of conditions. Each one targets a specific neuronal population, and that specificity determines symptoms, rate of progression, and genetic architecture. The table below summarises the key features of each condition.

Condition	Neurons Affected	Genetic Architecture	Key Genes
Alzheimer’s disease	Cholinergic neurons (nucleus basalis of Meynert); glutamatergic pyramidal neurons (hippocampus, entorhinal cortex)	Monogenic in rare early-onset cases; polygenic in common late-onset form	APP, PSEN1, PSEN2; APOE4 risk allele.⁹
Parkinson’s disease	Dopaminergic neurons (substantia nigra pars compacta)	Monogenic in 10 to 15% of familial cases; polygenic in sporadic majority	SNCA, LRRK2 (autosomal dominant); PINK1, Parkin, DJ-1 (autosomal recessive); GBA risk variant.⁵, ¹⁰
ALS	Upper motor neurons (primary motor cortex); lower motor neurons (brainstem and spinal cord anterior horn)	Monogenic in approximately 10% of familial cases; polygenic in sporadic cases	SOD1, C9orf72, FUS, TARDBP.¹¹
Huntington’s disease	Medium spiny neurons (striatum: caudate nucleus and putamen)	Fully monogenic, autosomal dominant, complete penetrance above 39 CAG repeats	HTT (CAG trinucleotide repeat expansion).³
Multiple sclerosis	Oligodendrocytes (primary target); secondary axonal injury from inflammation	Polygenic	HLA-DRB1 (largest genetic effect).¹²

Common Symptoms of Neurodegenerative Disorders

Condition	Early Symptoms	As Disease Progresses
Alzheimer’s disease	Episodic memory loss (recent events and names), word-finding difficulty, apathy, and mild disorientation	Aphasia, visuospatial failure, loss of daily functioning, and inability to recognise family members.⁴
Parkinson’s disease	Non-motor prodrome: anosmia, constipation, REM sleep behaviour disorder, and depression (often precede motor signs by years)	Resting tremor, bradykinesia, rigidity, postural instability, and eventual cognitive decline.^{5 ,}¹⁰
ALS	Progressive focal weakness: limb onset (arm or leg weakness) or bulbar onset (dysarthria, dysphagia); sensation preserved	Generalised paralysis, respiratory muscle failure; cognitive features in a subset of patients.¹¹
Huntington’s disease	Subtle choreiform movements (initially resembling fidgeting), irritability, cognitive slowing, psychiatric features	Full chorea, executive dysfunction, profound personality and behavioural change; onset typically in the fourth or fifth decade.³
Multiple sclerosis	Optic neuritis, Lhermitte’s sign, fatigue, limb weakness, sensory disturbance, bladder dysfunction	Spasticity, progressive disability accumulation with each relapse; in primary progressive MS, gradual decline without remission.¹²

Neurodegenerative Disorders: Clinical Diagnosis and the Role of Genetic Testing

The selective and progressive death of specific neuron populations defines neurodegenerative disorders. Each condition targets a particular region of the brain or nervous system, and that location determines what symptoms appear. This specificity is why early imaging and biomarker testing are so valuable.

Changes in CSF and plasma biomarkers, including amyloid-beta, phospho-tau, and neurofilament light chain, can now be detected before major symptoms appear, giving clinicians a window to act earlier.^2, ^11, ¹³ Genetic testing has become an indispensable layer of this diagnostic framework. It operates along two complementary lines.

Monogenic testing identifies single high-penetrance pathogenic variants with direct diagnostic certainty. A positive result in HTT confirms Huntington’s disease, in PSEN1 or APP it confirms familial Alzheimer’s disease, and in SOD1 or C9orf72 it confirms familial ALS. The result is not probabilistic: it is diagnostic, and it carries immediate implications for the extended family.^3,^11, ¹⁴

Polygenic risk scoring (PRS) addresses the far larger population of patients with complex, multifactorial disease. PRS aggregates hundreds of common low-effect variants into a single estimate of genetic liability.

In Alzheimer’s disease, PRS incorporating APOE status has demonstrated superior predictive value over APOE4 testing alone. In Parkinson’s disease, PRS can stratify individuals years before motor symptoms emerge, identifying those who merit closer surveillance or enrolment in prevention-focused trials.^{5 ,} ¹⁵

How genetic testing supports families extends well beyond the individual diagnosis:

Pre-symptomatic diagnosis: At-risk relatives can be tested before symptoms appear. A positive result for HTT or PSEN1 allows the individual to plan, make informed decisions about employment and care, and enter surveillance programmes at the earliest possible stage.
Understanding disease trajectory: CAG repeat length in Huntington’s disease correlates inversely with age of onset and rate of progression. In Parkinson’s disease, identifying a LRRK2 or GBA variant modifies prognostic expectations and informs therapeutic choices as genotype-specific trials advance.
Choosing the right treatment: Tofersen, approved for SOD1-ALS, is the first genotype-specific therapy for any neurodegenerative disorder. LRRK2 kinase inhibitors are in advanced clinical development. Genetic subtyping at diagnosis positions patients to access these therapies.²
Identifying at-risk family members: Cascade testing, the systematic genetic screening of relatives following an index diagnosis. This allows those at highest risk to be identified and monitored before neurological damage accumulates.
Enabling early intervention and reproductive planning: Families can engage with biomarker surveillance programmes, enrol in prevention trials, and make reproductive decisions with full information. Preimplantation genetic diagnosis is available for fully penetrant conditions, including Huntington’s disease and familial Alzheimer’s disease.¹⁶

Neurodegenerative Disease Management Approaches

While a definitive cure remains elusive for most neurodegenerative conditions, comprehensive management can significantly improve quality of life and functional independence. Current strategies include:

Pharmacological interventions: Medications are the frontline for symptom control. Levodopa remains the gold standard for managing motor symptoms in Parkinson’s disease. Cholinesterase inhibitors, including donepezil, galantamine, and rivastigmine, are the established first-line treatments for mild to moderate Alzheimer’s disease. Anti-amyloid antibodies (lecanemab, donanemab) represent the first approved disease-modifying therapies for Alzheimer’s disease.⁴
Rehabilitative therapies: Early intervention through physical, occupational, and speech therapy is critical. These programmes are designed to extend independence, improve mobility, and maintain communication skills as the disease progresses.
Genetic testing as a management tool: Genetic subtyping informs prognosis, determines eligibility for genotype-specific therapies, facilitates entry into clinical trials, and enables cascade screening of at-risk family members. It is now an integral part of the diagnostic workup for early-onset, familial, or atypical presentations.^2,¹⁶
Next-generation research: The landscape of treatment is shifting from symptom management to disease modification. Gene-targeted therapies and immunotherapies, including antisense oligonucleotides for Huntington’s disease and tau-directed therapies in Alzheimer’s disease, are in active clinical development.²

Neurodegenerative Disease Statistics Worldwide

An estimated 57 million people lived with dementia globally in 2019, a number projected to reach 153 million by 2050.¹⁷ These conditions are among the leading causes of long-term disability and caregiver burden across every region, with healthcare costs running into hundreds of billions annually. The scale is significant and growing.

Conclusion

Neurodegenerative disorders present a profound challenge, but our understanding of their genetic and biological foundations is expanding rapidly. While these conditions are progressive, early detection through advanced genetic screening and personalised management can significantly alter the care journey.

As research moves toward disease-modifying therapies, the role of precise genomic insights becomes even more critical. Monogenic testing delivers diagnostic certainty and enables cascade family screening.

Polygenic risk profiling identifies those who merit earlier surveillance and trial eligibility. MedGenome provides the comprehensive genetic testing necessary to help families and clinicians navigate these complexities with greater clarity and confidence.

Frequently Asked Questions

What are the most common neurodegenerative disorders?

The most prevalent neurodegenerative conditions are Alzheimer’s disease and Parkinson’s disease. Other common disorders include multiple sclerosis, amyotrophic lateral sclerosis (ALS), and Huntington’s disease. While they vary in clinical presentation, they all involve the progressive loss of neuronal structure or function.

Are neurodegenerative disorders hereditary?

The role of genetics varies. Huntington’s disease is fully monogenic; a single mutation guarantees inheritance with a 50% risk for offspring. Familial Alzheimer’s and ALS also follow strict genetic patterns. However, most cases are sporadic and polygenic, where multiple common variants collectively raise risk without dictating outcomes. Neuro genetic testing clarifies which mechanism applies.

How are they diagnosed?

Diagnosis requires combining neurological exams, cognitive testing, brain imaging (MRI/PET), and fluid biomarkers, as no single test suffices. Genetic testing is now critical for early-onset, atypical, or familial cases, enabling presymptomatic screening of at-risk relatives and determining eligibility for genotype-specific therapies and clinical trials.

Can they be slowed or managed?

Yes. While incurable, symptoms are managed using levodopa or cholinesterase inhibitors. Anti-amyloid therapies offer disease modification in early Alzheimer’s, and Tofersen is the first approved gene-directed therapy for SOD1-ALS. Physical therapies preserve independence, while genetic testing grants access to emerging genotype-specific clinical trials.

At what age do they usually begin?

Most manifest after age 60, but early-onset versions exist. Familial Alzheimer’s or Huntington’s typically strike in a person’s 30s or 40s, while ALS frequently begins between 40 and 70. A patient’s precise genetic profile directly dictates these age-of-onset expectations and guides early clinical surveillance planning.

References

Przedborski, S., M. Vila, and V. Jackson-Lewis. “Series Introduction: Neurodegeneration: What Is It and Where Are We?” Journal of Clinical Investigation 111, no. 1 (2003): 3-10.
https://www.jci.org/articles/view/17522
Gadhave, Dnyandev G., Vrashabh V. Sugandhi, Saurav Kumar Jha, Sopan N. Nangare, Gaurav Gupta, Sachin Kumar Singh, Kamal Dua, Hyunah Cho, Philip M. Hansbro, and Keshav Raj Paudel. “Neurodegenerative Disorders: Mechanisms of Degeneration and Therapeutic Approaches with Their Clinical Relevance.” Ageing Research Reviews 99 (2024): 102357.
https://www.sciencedirect.com/science/article/pii/S1568163724001752?via%3Dihub
Walker, F. O. “Huntington’s Disease.” The Lancet 369, no. 9557 (2007): 218-228.
https://pubmed.ncbi.nlm.nih.gov/17240289/
Scheltens, P., K. Blennow, M. M. B. Breteler, et al. “Alzheimer’s Disease.” The Lancet 388, no. 10043 (2016): 505-517.
https://pubmed.ncbi.nlm.nih.gov/26921134/
Nalls, Mike A., Cornelis Blauwendraat, Costanza L. Vallerga, Karl Heilbron, and Sara Bandres-Ciga. “Identification of Novel Risk Loci, Causal Insights, and Heritable Risk for Parkinson’s Disease: A Meta-Analysis of Genome-Wide Association Studies.” The Lancet Neurology 18, no. 12 (2019): 1091-1102. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(19)30320-5/abstract
Soto, C., and S. Pritzkow. “Protein Misfolding, Aggregation, and Conformational Strains in Neurodegenerative Diseases.” Nature Neuroscience 21, no. 10 (2018): 1332-1340. https://www.nature.com/articles/s41593-018-0235-9
Pezzoli, G., and E. Cereda. “Exposure to Pesticides or Solvents and Risk of Parkinson’s Disease.” Neurology 80, no. 22 (2013): 2035-2041. https://www.neurology.org/doi/10.1212/WNL.0b013e318294b3c8
McKee, Ann C., Robert A. Stern, Christopher J. Nowinski, Thor D. Stein, Victor E. Alvarez, and Daniel H. Daneshvar. “The Spectrum of Disease in Chronic Traumatic Encephalopathy.” Brain 136, no. 1 (2013): 43-64.
https://academic.oup.com/brain/article-abstract/136/1/43/433876
Alzheimer’s Association. “Alzheimer’s Disease Facts and Figures.” Accessed 2024.
https://www.alz.org/alzheimers-dementia/facts-figures
Dauer, W., and S. Przedborski. “Parkinson’s Disease: Mechanisms and Models.” Neuron 39, no. 6 (2003): 889-909.
https://pubmed.ncbi.nlm.nih.gov/12971891/
Masrori, P., and P. Van Damme. “Amyotrophic Lateral Sclerosis: A Clinical Review.” European Journal of Neurology 27, no. 10 (June 11, 2020): 1918–29.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7540334/
Reich, D. S., C. F. Lucchinetti, and P. A. Calabresi. “Multiple Sclerosis.” New England Journal of Medicine 378, no. 2 (2018): 169-180.
https://pubmed.ncbi.nlm.nih.gov/29320652/
Jack, Clifford R., David A. Bennett, Kaj Blennow, Maria C. Carrillo, Billy Dunn, Samantha Budd Haeberlein, and David M. Holtzman. “NIA-AA Research Framework: Toward a Biological Definition of Alzheimer’s Disease.” Alzheimer’s and Dementia 14, no. 4 (2018): 535-562. https://pmc.ncbi.nlm.nih.gov/articles/PMC5958625/
Xiao, X., Liu, H., Liu, X., Zhang, W., Zhang, S., & Jiao, B. (2021). APP, PSEN1, and PSEN2 Variants in Alzheimer’s Disease: Systematic Re-evaluation According to ACMG Guidelines. Frontiers in aging neuroscience, 13, 695808.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8249733/
Escott-Price, Valentina, Rebecca Sims, David Bannister, Harold de Kraker, Thomas Hanon, Robert Passmore, Sarah V. Patel, et al. “Common Polygenic Variation Enhances Risk Prediction for Alzheimer’s Disease.” Brain 138, no. 12 (December 2015): 3673–3684.
https://pmc.ncbi.nlm.nih.gov/articles/PMC5006219/
Roberts, J. S., M. Uhlmann, C. D. Royal, et al. “Genetic Testing for Neurodegenerative Diseases: Ethical and Health Communication Challenges.” Neurology and Genetics 6, no. 3 (2020): e416. https://pmc.ncbi.nlm.nih.gov/articles/PMC7311284/
GBD 2019 Dementia Forecasting Collaborators. “Estimation of the Global Prevalence of Dementia in 2019 and Forecasted Prevalence in 2050: An Analysis for the Global Burden of Disease Study 2019.” The Lancet Public Health 7, no. 2 (2022): e105-e125.
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00249-8/fulltext